Pular para o conteúdo
Displasia de alto grau em doentes com esôfago de Barrett
ORPHA:231080CID-10 · K22.7CID-11 · DA23.1DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Início todas idadesHerança Unknown

Esôfago de Barrett é uma condição na qual ocorre uma alteração anormal (metaplásica) nas células da mucosa que revestem a parte inferior do esôfago. As células mudam de epitélio escamoso estratificado para epitélio colunar simples, intercalado com células caliciformes que normalmente são encontradas apenas no intestino delgado e no intestino grosso. Essa alteração é considerada uma condição pré-maligna devido ao seu potencial de transição para adenocarcinoma esofágico, um câncer muitas vezes fatal.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEsboçohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

Mantido pelo Disease Twin100% com fonte · atualizado 09/06/2026Revisão médica pendente
Informacoes curadas por IA — podem conter imprecisoes

Visão geral

A displasia de alto grau em doentes com esôfago de Barrett é uma condição na qual as células que revestem o esôfago (o tubo que liga a boca ao estômago) apresentam alterações significativas, consideradas pré-cancerosas. O esôfago de Barrett é uma condição pré-existente, na qual o revestimento normal do esôfago é substituído por um tecido semelhante ao do intestino, geralmente como consequência de refluxo gastroesofágico crônico. A displasia de alto grau representa o estágio mais avançado dessas alterações celulares, com maior risco de progressão para câncer de esôfago. A prevalência estimada é de 1 a 5 casos para cada 10.000 pessoas.[1][2]

Sinais e sintomas

Os principais sinais e sintomas associados a esta condição incluem: esôfago de Barrett (a condição de base), disfagia (dificuldade para engolir), obstrução esofágica (sensação de alimento parado no peito) e refluxo gastroesofágico (azia e regurgitação ácida). É importante notar que a displasia de alto grau em si pode não causar sintomas adicionais, sendo frequentemente detectada durante exames de vigilância em pessoas com esôfago de Barrett.[1][2]

Causas genéticas

Até o momento, não há um gene específico identificado como causa direta da displasia de alto grau em doentes com esôfago de Barrett. A condição não é considerada hereditária no sentido clássico (herança não aplicável). As alterações celulares ocorrem ao longo do tempo, principalmente devido à exposição crônica ao ácido do estômago (refluxo gastroesofágico), que danifica o revestimento do esôfago e leva a mutações adquiridas (somáticas) nas células.[1][3]

Diagnóstico

O diagnóstico da displasia de alto grau é feito por meio de endoscopia digestiva alta com biópsia do esôfago. Durante o exame, o médico coleta pequenas amostras do tecido do esôfago de Barrett, que são analisadas ao microscópio por um patologista. A displasia de alto grau é classificada quando as células apresentam alterações marcantes em sua aparência e organização, indicando um risco elevado de progressão para câncer. Não há testes genéticos específicos (germinativos) recomendados para o diagnóstico, pois a condição não é causada por uma mutação hereditária.[1][3]

Tratamento e manejo

O manejo da displasia de alto grau em doentes com esôfago de Barrett é focado na prevenção da progressão para câncer de esôfago. As opções de tratamento incluem vigilância endoscópica rigorosa (endoscopias frequentes com biópsias) e procedimentos de ablação (como ablação por radiofrequência) ou ressecção endoscópica da área afetada. O controle do refluxo gastroesofágico com medicamentos (como inibidores da bomba de prótons) é fundamental para reduzir a irritação contínua do esôfago. A decisão sobre o tratamento deve ser individualizada, discutida com uma equipe médica especializada. Não há cobertura específica pelo Sistema Único de Saúde (SUS) para esta condição.[1]

Prognóstico e qualidade de vida

O prognóstico depende do estágio em que a displasia é detectada e da resposta ao tratamento. Quando identificada precocemente e tratada adequadamente, a progressão para câncer pode ser prevenida ou retardada na maioria dos casos. A qualidade de vida pode ser impactada pela necessidade de exames endoscópicos frequentes e pelo manejo dos sintomas de refluxo. O acompanhamento regular com um gastroenterologista é essencial para monitorar a condição e ajustar o tratamento conforme necessário.[1]

Fontes numeradas em Referências.

Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.

💬
EM LINGUAGEM SIMPLES

A **displasia de alto grau em doentes com esôfago de Barrett** é uma alteração celular avançada identificada na parede do esôfago. Ela costuma causar sintomas como **refluxo gastroesofágico** (sensação de queimação pelo retorno de ácido), **disfagia** (dificuldade de engolir) e **obstrução esofágica** (sensação de entalo). No Brasil, a condição não consta na lista oficial de PCDT de doenças raras e não possui medicamentos específicos fornecidos pelo SUS, devendo ser acompanhada nos serviços de referência da rede pública.

📋
Informacoes curadas por IA — podem conter imprecisoes

Esôfago de Barrett é uma condição na qual ocorre uma alteração anormal (metaplásica) nas células da mucosa que revestem a parte inferior do esôfago. As células mudam de epitélio escamoso estratificado para epitélio colunar simples, intercalado com células caliciformes que normalmente são encontradas apenas no intestino delgado e no intestino grosso. Essa alteração é considerada uma condição pré-maligna devido ao seu potencial de transição para adenocarcinoma esofágico, um câncer muitas vezes fatal.

Medicamentos
1 com registro
Photofrin (PORFIMER SODIUM)

Tem tratamento?

✓ 1 medicamento específico desta doença (registro ANVISA, FDA ou SUS/CEAF)
PHOTOFRIN (PORFIMER SODIUM)

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
36.0
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 20%
CID-10: K22.7
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Características mais comuns

90%prev.
Esôfago de Barrett
Muito frequente (99-80%)
55%prev.
Disfagia
Frequente (79-30%)
55%prev.
Refluxo gastroesofágico
Frequente (79-30%)
17%prev.
Obstrução esofágica
Ocasional (29-5%)
4sintomas
Muito frequente (1)
Frequente (2)
Ocasional (1)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 4 características clínicas mais associadas, ordenadas por frequência.

Esôfago de BarrettBarrett esophagus
Muito frequente (99-80%)90%
DisfagiaDysphagia
Frequente (79-30%)55%
Refluxo gastroesofágicoGastroesophageal reflux
Frequente (79-30%)55%
Obstrução esofágicaEsophageal obstruction
Ocasional (29-5%)17%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Últimos 10 anos200publicações
Pico202255 papers
Linha do tempo
2026Hoje · 2026📈 2022Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Displasia de alto grau em doentes com esôfago de Barrett

Centros de Referência SUS

24 centros habilitados pelo SUS para Displasia de alto grau em doentes com esôfago de Barrett

Centros para Displasia de alto grau em doentes com esôfago de Barrett

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Infantil Albert Sabin

R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Universitário da UFJF

R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442

Atenção Especializada

Rota
Anomalias Congênitas

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Julio Müller (HUJM)

R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092

Atenção Especializada

Rota
Anomalias Congênitas

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Lauro Wanderley (HULW)

R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470

Atenção Especializada

Rota
Anomalias Congênitas

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Pequeno Príncipe

R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital Universitário Regional de Maringá (HUM)

Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Base de São José do Rio Preto

Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

The Impact of Hiatus Hernia Size on Dysplasia Progression in Patients With Barrett's Esophagus.

JGH open : an open access journal of gastroenterology and hepatology2026 Mar

Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma, a condition with high morbidity and mortality and rapidly rising incidence in the Western population. Hiatus hernias increase exposure to acid and bile in the esophagus, driving epithelial damage that eventually leads to BE and dysplasia. Evidence is limited regarding the influence of hiatus hernias on dysplasia progression in BE, particularly in the modern era of endoscopy. We conducted a retrospective analysis of a prospectively maintained database, including patients undergoing surveillance endoscopy for BE at a single Australian tertiary center from 1999 to 2025. Endoscopic and histological data were recorded from all surveillance endoscopies and stratified according to the presence and size of hiatus hernia. A total of 547 patients with BE were included, of whom 72.8% were male. 46.6% (n = 255) had a hiatus hernia measuring ≥ 3 cm. Progression of dysplasia during the study period was more common in those with a ≥ 3 cm hiatus hernia (13.7% vs. 3.8%; HR 3.12, p = 0.001), as was progression to at least high-grade dysplasia (10.2% vs. 1.6%; HR 2.65, p = 0.012). There was a corresponding reduction in progression-free survival in the ≥ 3 cm hiatus hernia group (128 months vs. 189, p < 0.001). Hiatus hernias, particularly those measuring ≥ 3 cm, significantly increase the likelihood of dysplasia progression in BE. Patients with ≥ 3 cm hiatus hernias should be considered high risk when undertaking endoscopic treatment and surveillance. Further research is required to establish the role of antireflux surgery in parallel with resection and eradication therapy.

#2

Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis.

The American journal of gastroenterology2026 Feb 25

The adjunctive use of p53 immunohistochemistry (IHC) has been proposed as a potential tool to improve risk stratification in Barrett's esophagus (BE) with conflicting results. We performed a systematic review and meta-analysis to evaluate the performance of p53 in predicting progression to advanced neoplasia [high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC)] among patients with BE. We searched multiple databases for studies that evaluated the use of aberrant p53 in esophageal biopsies among BE patients and reported progression rates to HGD/EAC. The outcomes were p53 test characteristics and incidence and risk ratio (RR) for progression to HGD/EAC in patients with and without aberrant p53 using random effects models. Among the 27 included studies, the proportion of patients with aberrant p53 expression at baseline was 20% (95% CI: 14%, 27%). The rate of progression with and without aberrant p53 was 8 per 100 person-years (95% CI: 6, 11) and 0.3 per 100 person-years (95% CI: 0.1, 0.6), respectively. Compared to patients without aberrant p53 expression, those with aberrant p53 had a higher risk for progression to HGD/EAC in cohort studies [RR = 10.2 (95% CI: 6.9, 15.0)] and case control studies [RR = 3.3 (95% CI: 2.5, 4.4)]. The sensitivity for progression for NDBE and low-grade dysplasia/indefinite for dysplasia was 42% and 77% and specificity was 96% and 76%, respectively. While aberrant p53 expression has been associated with an increased risk of progression to advanced neoplasia in BE patients undergoing surveillance, the diagnostic characteristics are suboptimal precluding uniform clinical adoption. Prospective studies with standardized grading protocols are needed to determine whether p53-guided surveillance strategies can meaningfully improve patient outcomes.

#3

Clinical Utility of Biomarkers for Barrett's Esophagus: Guidelines and Future Directions.

Gastroenterology clinics of North America2026 Mar

Barrett's esophagus (BE) is a major risk factor for the development of esophageal adenocarcinoma (EAC) and is the only known precursor lesion for this lethal cancer. Although BE is relatively common among patients with gastroesophageal reflux disease, most patients with BE will never progress to EAC. Moreover, the cadence of progression from nondysplastic BE to dysplasia to EAC may be variable. The histologic grading of dysplasia during endoscopy is the most widely used prognosticator for risk stratification and management of BE based on its stepwise progression from low-grade dysplasia to high-grade dysplasia to mucosal EAC, and finally, to invasive EAC.

#4

A machine-learning informed circulating microbial DNA signature for early diagnosis of esophageal adenocarcinoma.

Gut microbes2026 Dec 31

Esophageal adenocarcinoma (EAC) has seen a dramatic rise in incidence in developed countries over the past three decades. Early detection of its precursors-gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and high-grade dysplasia (HGD) is critical for cancer prevention. This study presents the development and validation of a novel liquid biopsy assay based on circulating microbial DNA (cmDNA) for the early detection of EAC and HGD. Using metagenomic sequencing, we identified significant differences in microbial diversity and composition between EAC and HGD patients, as well as between BE and GERD patients. A total of 46 microbial candidates in tissue and 419 in serum were upregulated in EAC & HGD, with 11 consistently elevated in both sample types. Following qRT-PCR validation and LASSO regression, a 6-marker cmDNA panel was selected. This signature was incorporated into a diagnostic model trained with the XGBoost algorithm, achieving an AUC of 0.93 in the training cohort (52 HGD & EAC cases vs. 54 BE & GERD controls). Importantly, the model demonstrated robust performance in an independent testing cohort (23 HGD & EAC cases vs. 22 BE & GERD controls), yielding AUCs of 0.91 for EAC and 0.88 for HGD. These findings highlight the diagnostic potential of cmDNA-based profiling and support its utility as a minimally invasive, accurate, and generalizable tool for early detection of esophageal adenocarcinoma.

#5

The Tissue Systems Pathology Test Predicts Risk of Progression in Patients With Barrett's Esophagus: Systematic Review and Meta-Analysis.

Journal of clinical gastroenterology2026 Apr 01

A systematic review and meta-analysis of published clinical validity studies was conducted to evaluate the predictive performance of the TSP-9 test. Identifying patients with Barrett's esophagus (BE) who will progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) is challenging. The tissue systems pathology (TSP-9) test can predict risk of progression to HGD/EAC in BE patients. Databases were searched for studies that assessed the clinical validity of TSP-9, and data describing progressors, non-progressors, TSP-9 results, and hazard ratios (HR) with 95% confidence intervals (CIs) were extracted. Odds ratios (OR), sensitivity, specificity, and prevalence-adjusted positive and negative predictive values (PPV adj /NPV adj ) were calculated and used for meta-analysis. Six studies met eligibility criteria, comprising 699 patients. ORs and HRs for TSP-9 had mean common effect size estimates of 6.52 (95% CI: 4.40-9.66, P <0.0001, I2 =33%) and 6.66 (95% CI: 4.59-9.66, P <0.0001, I2 =0%), respectively, for predicting progression to HGD/EAC. Mean common effect size estimates were 61% (95% CI: 54%-68%) for sensitivity, 81% (95% CI: 78%-84%) for specificity, 28% (95% CI: 17%-42%) for PPV adj (high risk), 14% (95% CI: 9%-21%) for PPV adj (high/int risk), and 97% (95% CI: 96%-98%) for NPV adj with minimal inter-study heterogeneity ( I2 =79%, 21%, 0%, 0%, and 0%, respectively). Effect estimates of TSP-9 performance demonstrate that the test provides risk stratification for BE patients. The TSP-9 test can provide clinically impactful results to enable escalation of care for high-risk patients or to identify low-risk patients who can be safely managed with routine surveillance.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 200

2026

The Impact of Hiatus Hernia Size on Dysplasia Progression in Patients With Barrett's Esophagus.

JGH open : an open access journal of gastroenterology and hepatology
2026

Recurrent Barrett's esophagus-related neoplasia is uncommon after successful endoscopic eradication therapy over long-term follow-up.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2026

Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis.

The American journal of gastroenterology
2026

SOX9 protein in goblet cells as a critical mediator and potential therapeutic target in Barrett's esophagus: An integrated bioinformatics analysis.

International journal of biological macromolecules
2025

Barrett High-Grade Dysplasia and Early Esophageal Adenocarcinoma in Patients With Positive Results on a Nonendoscopic Methylated DNA Biomarker Test.

Gastroenterology &amp; hepatology
2026

Characteristics and causes of post-endoscopy Barrett's neoplasia: Retrospective multicenter study.

Endoscopy international open
2026

Clinical Utility of Biomarkers for Barrett's Esophagus: Guidelines and Future Directions.

Gastroenterology clinics of North America
2026

An early-stage adenocarcinoma originating from a 15-cm long-segment Barrett's esophagus: A case report.

Medicine
2025

The Evolving Paradigm of Esophageal and Esophagogastric Junction Adenocarcinoma: Current Insights, Emerging Therapies, and Future Directions.

Journal of cancer science and clinical therapeutics
2025

[Prevalence of Barrett's esophagus and factors associated with the diagnosis of dysplasia or adenocarcinoma in patients evaluated at a Chilean university endoscopy center].

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru
2025

The Impact of Neoadjuvant Chemoradiation Therapy on Non-Tumorous Barrett's Dysplasia of the Esophagus: A Multicenter Cohort Study.

Journal of clinical medicine
2026

Crypt Dysplasia is a Risk Factor for the Development of High-Grade Dysplasia/Adenocarcinoma in Barrett Esophagus.

The American journal of surgical pathology
2026

A machine-learning informed circulating microbial DNA signature for early diagnosis of esophageal adenocarcinoma.

Gut microbes
2025

Evaluating the Efficacy and Safety of Radiofrequency Ablation Compared to Endoscopic Surveillance in Managing Low-Grade Dysplasia in Barrett's Esophagus: A Systematic Review and Meta-Analysis.

Cureus
2025

Esophageal Function Testing Identifies Barrett's Esophagus Patients With Pathological Acid Exposure at Risk for Neoplasia.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2025

Durability of cryoballoon ablation for eradication of neoplastic Barrett's esophagus: a multicenter prospective cohort study (with video).

Gastrointestinal endoscopy
2025

Risk stratification for progression to adenocarcinoma and high-grade dysplasia in Barrett's esophagus: a cohort study from an expert Spanish center.

Revista espanola de enfermedades digestivas
2025

AI-Driven Risk Prediction Tool (TSP-9) Informs Risk-Aligned Care for Patients with Barrett's Esophagus.

Diagnostics (Basel, Switzerland)
2025

Cancer Burden on Piecemeal Endoscopic Resection of Early Adenocarcinoma in Barrett's Oesophagus Correlates With the Risk of Neoplastic Recurrence.

United European gastroenterology journal
2026

The Tissue Systems Pathology Test Predicts Risk of Progression in Patients With Barrett's Esophagus: Systematic Review and Meta-Analysis.

Journal of clinical gastroenterology
2025

Research Communication: Prevalence of Asymptomatic Premalignant Oesophageal Lesions in Patients With Fanconi Anaemia.

Alimentary pharmacology &amp; therapeutics
2026

Discovery and Validation of Molecular Biomarkers for Differentiation of Nondysplastic Barrett's Esophagus from High-grade Dysplasia and Esophageal Adenocarcinoma.

Cancer prevention research (Philadelphia, Pa.)
2025

Margin clearance and post-procedure ablation decrease recurrence risk in endoscopic mucosal resections for Barrett's-related neoplasia.

Histopathology
2025

Global Hypomethylation as Minimal Residual Disease (MRD) Biomarker in Esophageal and Esophagogastric Junction Adenocarcinoma.

Cancers
2025

Precision Care in Screening, Surveillance, and Overall Management of Barrett's Esophagus.

Journal of personalized medicine
2025

Increased reflux secondary bile acids are associated with changes to the microbiome and transcriptome in Barrett's esophagus.

Gut microbes
2025

Circumferential endoscopic submucosal dissection of a 14-cm long-segment Barrett's esophagus with multifocal adenocarcinoma: a case report.

VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy
2025

Tackling Prevention and Early Diagnosis of Esophageal Adenocarcinoma Through a National Barrett's Registry and Scientific Network.

Annals of surgery
2025

Efficacy and Safety of Advanced Endoscopic Techniques in Early Barrett's Neoplasia: A Systematic Review and Pooled Analysis.

Cureus
2025

LncRNA small nucleolar RNA host gene 1 (SNHG1) mediates acidic bile salt-induced EMT via the ULK1-Notch1 axis in Barrett's esophagus.

Molecular biomedicine
2025

Distal esophageal acid exposure and poor esophageal clearance correlate with probability of progression in Barrett's esophagus as determined by the tissue systems pathology test.

Surgical endoscopy
2025

Endoscopic mucosal resection for Barrett's neoplasia: Long-term outcomes from the largest Canadian single-center experience.

Endoscopy international open
2025

Endoscopic calcium electroporation in patients with precancerous cellular changes in the esophagus.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2025

Biomarker risk stratification with capsule sponge in the surveillance of Barrett's oesophagus: prospective evaluation of UK real-world implementation.

Lancet (London, England)
2026

Texture and Colour Enhancement Imaging versus White Light Endoscopy for Detection of Dysplasia within Barrett's Oesophagus: A Pilot Study.

Digestion
2025

Cost-Effectiveness of Regular Surveillance Versus Endoscopy at Need for Patients With Barrett's Esophagus: Economic Evaluation Alongside the Barrett's Oesophagus Surveillance Study (BOSS) Randomized Controlled Trial.

Gastroenterology
2025

Impact on Barrett's dysplasia yield following the introduction of capsule sponge testing versus traditional endoscopic surveillance.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2025

L1 Capsid Protein Expression in HPV-Positive Barrett Metaplasia-Dysplasia-Adenocarcinoma Lesions.

Clinical and translational gastroenterology
2026

Indefinite for dysplasia in Barrett's esophagus carries substantial risk for prevalent and incident neoplasia: updated outcomes and long-term follow-up.

Gastrointestinal endoscopy
2026

The future is now: advancing p53 immunohistochemistry in Barrett's oesophagus and its implication for the everyday pathologist.

Histopathology
2025

Gastric (Foveolar)-Type Dysplasia in Barrett's Esophagus: A Clinical, Molecular, and Long-Term Outcome Study.

The American journal of gastroenterology
2025

Prevalence of intestinal metaplasia, dysplasia, and esophageal adenocarcinoma in patients with irregular Z-line: a systematic review and meta-analysis.

Clinical endoscopy
2025

Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells.

Gastroenterology
2025

Neutrophil-Lymphocyte Ratio May be Used as a Biomarker for Predicting Progression of Barrett's Esophagus to Esophageal Adenocarcinoma: A Retrospective Cohort Study.

JGH open : an open access journal of gastroenterology and hepatology
2025

Efficacy and safety of H-APC in Barrett's esophagus: Italian prospective multicenter study.

Endoscopy international open
2025

Natural course of high-grade dysplasia in Barrett's esophagus: a scoping review and case series.

Gastrointestinal endoscopy
2025

Surveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease-Specific Mortality.

United European gastroenterology journal
2025

Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Patients With Barrett Esophagus.

The American journal of gastroenterology
2025

Discovery of Methylated DNA Biomarkers for Potential Nonendoscopic Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.

The American journal of gastroenterology
2025

Histological features indicate the risk of progression of patients with Barrett's esophagus.

Pathology, research and practice
2024

Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett's esophagus: a retrospective cohort study in Sweden.

Clinical endoscopy
2025

Neoplastic Progression Risk in Females With Barrett's Esophagus: A Systematic Review and Meta-Analysis of Individual Patient Data.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2024

Analytical Validation of Esopredict, an Epigenetic Prognostic Assay for Patients with Barrett's Esophagus.

Diagnostics (Basel, Switzerland)
2024

Narrow band imaging: Important tool for early diagnosis, management, and improved outcomes in gastrointestinal lesions.

World journal of surgery
2024

Outcomes of patients with Barrett's oesophagus with low-grade dysplasia undergoing endoscopic surveillance in a tertiary centre: a retrospective cohort study.

Internal medicine journal
2025

The Association Between Obesity and Malignant Progression of Barrett's Esophagus: A Systematic Review and Dose-Response Meta-Analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2025

Recurrence following successful eradication of neoplasia with endoscopic mucosal resection compared with endoscopic submucosal dissection in Barrett's esophagus: a retrospective comparison.

Endoscopy
2025

Can optical evaluation distinguish between T1a and T1b esophageal adenocarcinoma: an international expert interobserver agreement study.

Endoscopy
2024

Validation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett Esophagus.

The American journal of gastroenterology
2023

[Barrett's Esophagus: Update on the Diagnosis and Treatment. Review].

Revista medica de Chile
2024

Irregular Z-Line: To Biopsy or Not to Biopsy?

Digestive diseases and sciences
2025

Steroid lifting method during endoscopic submucosal dissection: A novel strategy for stricture prevention.

DEN open
2025

Preinjection With Ligation-Assisted Endoscopic Mucosal Resection for Barrett's Dysplasia and Early Esophageal Adenocarcinoma: Characteristic Histological Features of the Depth of Resection.

Journal of clinical gastroenterology
2024

The Aberrant Expression of Biomarkers and Risk Prediction for Neoplastic Changes in Barrett's Esophagus-Dysplasia.

Cancers
2024

Design and Evaluation of ScanCap: A Low-Cost, Reusable Tethered Capsule Endoscope with Blue-Green Illumination Imaging for Unsedated Screening and Early Detection of Barrett's Esophagus.

Bioengineering (Basel, Switzerland)
2024

AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.

Gastroenterology
2024

Oesophageal cell collection device and biomarker testing to identify high-risk Barrett's patients requiring endoscopic investigation.

The British journal of surgery
2024

Multicenter, Prospective Trial of Nonendoscopic Biomarker-Driven Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.

The American journal of gastroenterology
2024

Safety and efficacy of salvage endoscopic submucosal dissection for Barrett's neoplasia recurrence after radiofrequency ablation.

Endoscopy
2024

Trends in prevalence of esophageal adenocarcinoma: Findings from a statewide database of over 6 million patients.

Endoscopy international open
2024

CDKN2A-p16 Deletion and Activated KRASG12D Drive Barrett's-Like Gland Hyperplasia-Metaplasia and Synergize in the Development of Dysplasia Precancer Lesions.

Cellular and molecular gastroenterology and hepatology
2024

Liquid nitrogen spray cryotherapy for eradication of dysplastic Barrett's esophagus: results from a multicenter prospective registry.

Gastrointestinal endoscopy
2024

Variation in proliferative and cell cycle markers in Barrett's esophagus in relation to circumferential and axial location in the esophagus.

European journal of gastroenterology &amp; hepatology
2024

Incidence rates of Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis.

iGIE : innovation, investigation and insights
2023

Feasibility Study Utilizing NanoString's Digital Spatial Profiling (DSP) Technology for Characterizing the Immune Microenvironment in Barrett's Esophagus Formalin-Fixed Paraffin-Embedded Tissues.

Cancers
2024

The Salivary Microbiome and Predicted Metabolite Production Are Associated with Barrett's Esophagus and High-Grade Dysplasia or Adenocarcinoma.

Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2024

WATS 3D : An Interobserver Study of Barrett's Esophagus-Associated Dysplasia Among Gastrointestinal Pathologists.

Clinical and translational gastroenterology
2024

Significance of Crypt Atypia in Barrett's Esophagus: A Clinical, Molecular, and Outcome Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2024

The impact of endoscopic treatment on health-related quality of life in patients with Barrett's neoplasia: a scoping review.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
2023

Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

Endoscopy
2024

Significant Reduction in the Diagnosis of Barrett's Esophagus and Related Dysplasia During the COVID-19 Pandemic.

The American journal of gastroenterology
2024

A Randomized Controlled Study on Clinical Adherence to Evidence-Based Guidelines in the Management of Simulated Patients With Barrett's Esophagus and the Clinical Utility of a Tissue Systems Pathology Test: Results From Q-TAB.

Clinical and translational gastroenterology
2023

The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia.

Gastroenterology
2023

Optimizing Storage and Computational Efficiency: An Efficient Algorithm for Whole Slide Image Size Reduction.

Mayo Clinic proceedings. Digital health
2023

A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients With Barrett's Esophagus.

Clinical and translational gastroenterology
2023

Impact of Residing in Below Median Household Income Districts on Outcomes in Patients with Advanced Barrett's Esophagus.

Journal of the Canadian Association of Gastroenterology
2023

Impact of race/ethnicity and socioeconomic status on incident and prevalent esophageal cancer in patients with Barrett's esophagus.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2023

The Salivary Microbiome and Predicted Metabolite Production are Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.

bioRxiv : the preprint server for biology
2023

Role of Confocal Laser Endomicroscopy in Early Detection of Upper Gastrointestinal Malignancy in High Risk Patients.

Asian Pacific journal of cancer prevention : APJCP
2023

Fibroblast Activation Protein-α (FAP) Identifies Stromal Invasion in Colorectal Neoplasia.

The American journal of surgical pathology
2023

Long-term outcomes following successful endoscopic treatment of T1 esophageal adenocarcinoma: a multicenter cohort study.

Gastrointestinal endoscopy
2023

NON-ENDOSCOPIC ESOPHAGEAL SAMPLING DEVICE AND BIOMARKER PANEL FOR DETECTION OF BARRETT'S ESOPHAGUS (BE) AND ESOPHAGEAL ADENOCARCINOMA (EAC).

medRxiv : the preprint server for health sciences
2023

An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients With Barrett's Esophagus.

The American journal of gastroenterology
2023

Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.

Gastroenterology
2023

Neoplastic Progression of Barrett's Esophagus Among Organ Transplant Recipients: a Retrospective Cohort Study.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
2023

Degree of crypt atypia correlates with progression to high-grade dysplasia/adenocarcinoma in non-dysplastic Barrett's oesophagus.

Histopathology
2023

Cost-effectiveness Analysis of Radiofrequency Ablation in Patients With Barrett Esophagus and High-grade Dysplasia or Low-grade Dysplasia.

Clinical therapeutics
2023

What Is "Cold" and What Is "Hot" in Mucosal Ablation for Barrett's Oesophagus-Related Dysplasia: A Practical Guide.

Life (Basel, Switzerland)
2023

Seattle Protocol Is More Effective in Detection of Dysplasia Compared to Technology-Assisted Targeted Biopsies in Patients with Barrett's Esophagus.

Journal of clinical medicine
2023

Extrachromosomal DNA in the cancerous transformation of Barrett's oesophagus.

Nature
2023

Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States.

Medicine
2023

Real-world evidence of safety and effectiveness of Barrett's endoscopic therapy.

Gastrointestinal endoscopy
2023

Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett's Esophagus, and Barrett's Esophagus-Related Neoplasia in the United States.

Journal of health economics and outcomes research
2023

Radio frequency ablation of dysplastic Barrett's esophagus: Outcomes of a single-center registry.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
2023

[Current status in Barrett's esophagus].

Deutsche medizinische Wochenschrift (1946)
2023

The effect of procedural time on dysplasia detection rate during endoscopic surveillance of Barrett's esophagus.

Endoscopy
2023

Clinical consequences of nonadherence to Barrett's esophagus surveillance recommendations: a Multicenter prospective cohort study.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2023

Development and validation of a prediction model for histologic progression in patients with nondysplastic Barrett's esophagus.

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
2022

Advancements in photodynamic therapy of esophageal cancer.

Frontiers in oncology
2023

Long-term fear of cancer recurrence in patients treated endoscopically for early Barrett's neoplasia.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2022

Safety and efficacy of liquid nitrogen spray cryotherapy in Barrett's neoplasia - a comprehensive review and meta-analysis.

Endoscopy international open
2022

Utility of wide-area transepithelial sampling with 3-dimensional computer-assisted analysis as an adjunct to forceps biopsy sampling in the surveillance of patients with Barrett's esophagus after endoscopic eradication therapy.

iGIE : innovation, investigation and insights
2022

Utilization trends for endoscopic ablation therapy and esophagectomy in Barrett's esophagus from 2005 to 2019.

Scientific reports
2023

Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.

Histopathology
2023

Low-grade dysplasia in Barrett's esophagus: A problematic diagnosis.

Gastroenterologia y hepatologia
2023

High proficiency of esophageal endoscopic submucosal dissection with a "tunnel + clip traction" strategy: a large French multicentric study.

Surgical endoscopy
2023

A Consensus Diagnosis Utilizing Surface KI-67 Expression as an Ancillary Marker in Low-Grade Dysplasia Helps Identify Patients at High Risk of Progression to High-Grade Dysplasia and Esophaegal Adenocarcinoma.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2023

Serological levels of IGF-1 and IGFBP-3 in patients with Barrett's esophagus and esophageal adenocarcinoma: Longitudinal study.

Gastroenterologia y hepatologia
2022

Management of Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma.

Gastroenterology clinics of North America
2023

Barrett's oesophagus with indefinite for dysplasia shows high rates of prevalent and incident neoplasia in a UK multicentre cohort.

Journal of clinical pathology
2023

Wide-area transepithelial sampling with computer-assisted analysis to detect high grade dysplasia and cancer in Barrett's esophagus: a multicenter randomized study.

Endoscopy
2023

Using Natural Language Processing to Automatically Identify Dysplasia in Pathology Reports for Patients With Barrett's Esophagus.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2022

Characterizing isoform switching events in esophageal adenocarcinoma.

Molecular therapy. Nucleic acids
2022

Barrett esophagus frequency and predictors of dysplasia or cancer in Barrett esophagus.

European review for medical and pharmacological sciences
2023

Increased PXR and Suppressed T-Cell Signaling Are Associated With Malignant Degeneration of Barrett's Esophagus.

Gastro hep advances
2022

Diagnostic Accuracy of Artificial Intelligence (AI) to Detect Early Neoplasia in Barrett's Esophagus: A Non-comparative Systematic Review and Meta-Analysis.

Frontiers in medicine
2022

Sex Differences in Neoplastic Progression in Barrett's Esophagus: A Multicenter Prospective Cohort Study.

Cancers
2022

hERG1 Potassium Channel Expression in Colorectal Adenomas: Comparison with Other Preneoplastic Lesions of the Gastrointestinal Tract.

Current issues in molecular biology
2022

Development of a deep learning model for the histologic diagnosis of dysplasia in Barrett's esophagus.

Gastrointestinal endoscopy
2022

The concordance between wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS-3D) and standard endoscope biopsy in the detection of Barrett's esophagus and esophageal dysplasia.

Annals of diagnostic pathology
2022

Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach.

Frontiers in immunology
2022

Laparoscopic total fundoplication is superior to medical treatment for reducing the cancer risk in Barrett's esophagus: a long-term analysis.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2022

Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett's esophagus: a matched case-control study.

Virchows Archiv : an international journal of pathology
2022

A personalized and dynamic risk estimation model: The new paradigm in Barrett's esophagus surveillance.

PloS one
2022

Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.

Scandinavian journal of gastroenterology
2022

[Endoscopic Interventional Treatment of Precancerous Lesions and Early Carcinoma of the Esophagus - Criteria and Techniques of Local Ablation and Resection].

Therapeutische Umschau. Revue therapeutique
2022

[GERD and Barett: Natural Course of One Disease - Update Diagnostics and Therapy].

Therapeutische Umschau. Revue therapeutique
2022

Surveillance After Treatment of Barrett's Esophagus Benefits Those With High-Grade Dysplasia or Intramucosal Cancer Most.

The American journal of gastroenterology
2022

Surveillance of Barrett's esophagus using wide-area transepithelial sampling: systematic review and meta-analysis.

Endoscopy international open
2023

Adherence to Surveillance Endoscopies Posteradication of Barrett's Esophagus With High-grade Dysplasia or Carcinoma In Situ.

Journal of clinical gastroenterology
2022

Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.

The American journal of gastroenterology
2022

Barrett's esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies.

World journal of gastrointestinal oncology
2022

Barrett's esophagus: results from an Italian cohort with tight endoscopic surveillance.

Acta bio-medica : Atenei Parmensis
2022

Dysplastic Recurrence After Successful Treatment for Early Barrett's Neoplasia: Development and Validation of a Prediction Model.

Gastroenterology
2022

Detection of Barrett's neoplasia with a near-infrared fluorescent heterodimeric peptide.

Endoscopy
2022

Development and External Validation of a Model to Predict Complex Treatment After Radiofrequency Ablation for Barrett's Esophagus With Early Neoplasia.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2022

The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia.

Histopathology
2022

[Management of complicated Barrett's esophagus. Observational study carried out in a regional hospital].

Revue medicale de Liege
2022

Optimized Surveillance Intervals Following Endoscopic Eradication of Dysplastic Barrett's Esophagus: An International Cohort Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2022

Prediction of Progression in Barrett's Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2022

Endoscopic eradication therapy for Barrett's esophagus-related neoplasia: a final 10-year report from the UK National HALO Radiofrequency Ablation Registry.

Gastrointestinal endoscopy
2022

Expression of DNA Mismatch Repair Proteins, PD1 and PDL1 in Barrett's Neoplasia.

Cancer genomics &amp; proteomics
2021

Risk of esophageal adenocarcinoma in patients with Barrett's esophagus using proton pump inhibitors: a systematic review with meta-analysis and sequential trial analysis.

Translational cancer research
2022

Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitals.

Endoscopy
2022

Prediction of neoplastic progression in Barrett's esophagus using nanoscale nuclear architecture mapping: a pilot study.

Gastrointestinal endoscopy
2022

Recommendations for endoscopic surveillance after esophageal atresia repair in adults.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2022

Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.

The Lancet. Oncology
2022

External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans.

Gastrointestinal endoscopy
2022

Benefit of radiofrequency ablation after widespread endoscopic resection of neoplastic Barrett's esophagus in daily practice.

Annals of gastroenterology
2021

Benefit, tolerance, and safety of hybrid argon plasma coagulation for treatment of Barrett's esophagus: US pilot study.

Endoscopy international open
2022

Multicenter randomized controlled trial comparing forceps biopsy sampling with wide-area transepithelial sampling brush for detecting intestinal metaplasia and dysplasia during routine upper endoscopy.

Gastrointestinal endoscopy
2022

Targeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett's esophagus.

European journal of nuclear medicine and molecular imaging
2022

Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.

Expert review of clinical pharmacology
2021

Prevalence of Barrett's esophagus in a Southern European country: a multicenter study.

European journal of gastroenterology &amp; hepatology
2022

Gender differences in Barrett's esophagus and progression of disease: a systematic review and meta-analysis.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2022

Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia.

Gastroenterology
2022

Predictors of recurrence of dysplasia or cancer in patients with dysplastic Barrett's esophagus following complete eradication of dysplasia: a single-center retrospective cohort study.

Surgical endoscopy
2021

Machine learning for grading and prognosis of esophageal dysplasia using mass spectrometry and histological imaging.

Computers in biology and medicine
2022

Extending treatment criteria for Barrett's neoplasia: results of a nationwide cohort of 138 endoscopic submucosal dissection procedures.

Endoscopy
2021

The natural history of low-grade dysplasia in Barrett's esophagus and risk factors for progression.

JGH open : an open access journal of gastroenterology and hepatology
2022

Videoconference microscopy is a reliable alternative to conventional microscopy in the evaluation of Barrett's esophagus: Zooming into a new era.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2022

Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis.

Gastrointestinal endoscopy
2022

Progression of Barrett's esophagus, crypt dysplasia, and low-grade dysplasia diagnosed by wide-area transepithelial sampling with 3-dimensional computer-assisted analysis: a retrospective analysis.

Gastrointestinal endoscopy
2022

Nonthermal resection device for ablation of Barrett's esophagus: a feasibility and safety study.

Endoscopy
2021

Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.

Scientific reports
2022

Endoscopic submucosal dissection vs. endoscopic mucosal resection for early Barrett's neoplasia in the West: a retrospective study.

Endoscopy
2021

Not all low grade dysplasia in Barrett's oesophagus is the same: using specific histological criteria in predicting progression to neoplasia.

Pathology
2021

Systematic review with meta-analysis: the effects of family history on the risk of Barrett's oesophagus and oesophageal adenocarcinoma.

Alimentary pharmacology &amp; therapeutics
2021

Systematic review with meta-analysis: neoplasia detection rate and post-endoscopy Barrett's neoplasia in Barrett's oesophagus.

Alimentary pharmacology &amp; therapeutics
2021

Diagnostic Performance of Artificial Intelligence-Based Models for the Detection of Early Esophageal Cancers in Barret's Esophagus: A Meta-Analysis of Patient-Based Studies.

Cureus
2021

Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.

United European gastroenterology journal
2021

Systematic review with meta-analysis: the long-term efficacy of Barrett's endoscopic therapy-stringent selection criteria and a proposal for definitions.

Alimentary pharmacology &amp; therapeutics
2021

Evolution of re-epithelialization postcircumferential esophageal endoscopic submucosal dissection.

VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy
2021

Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2021

Impact of bariatric surgery on surveillance and treatment outcomes of Barrett's esophagus: A stage-matched cohort study.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
2022

Incidence and outcomes of poor healing and poor squamous regeneration after radiofrequency ablation therapy for early Barrett's neoplasia.

Endoscopy
2021

Epidemiology of Barrett's Esophagus and Esophageal Carcinoma.

The Surgical clinics of North America
2021

Barrett's esophagus with low-grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated.

Gastrointestinal endoscopy
2021

Liquid nitrogen spray cryotherapy for intramucosal carcinoma and extensive gastric intestinal metaplasia with dysplasia.

VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy
2021

Tissue Systems Pathology Test Objectively Risk Stratifies Barrett's Esophagus Patients With Low-Grade Dysplasia.

The American journal of gastroenterology
2021

Taking the Next Steps in Endoscopic Visual Assessment of Barrett's Esophagus: A Pilot Study.

Clinical and experimental gastroenterology
2022

Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2022

Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2021

Randomized Controlled Trial of the Gastrin/CCK2 Receptor Antagonist Netazepide in Patients with Barrett's Esophagus.

Cancer prevention research (Philadelphia, Pa.)
2021

Loss of SMAD4 Is Sufficient to Promote Tumorigenesis in a Model of Dysplastic Barrett's Esophagus.

Cellular and molecular gastroenterology and hepatology
2021

Post-ablation buried neoplasia in Barrett's esophagus.

Scandinavian journal of gastroenterology
2022

Long-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period.

Gut
2021

TissueCypher Barrett's esophagus assay impacts clinical decisions in the management of patients with Barrett's esophagus.

Endoscopy international open
2021

Longitudinal and Circumferential Distributions of Dysplasia and Early Neoplasia in Barrett's Esophagus: A Pooled Analysis of Three Prospective Studies.

Clinical and translational gastroenterology
2021

Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.

Journal of cancer research and clinical oncology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Displasia de alto grau em doentes com esôfago de Barrett.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Displasia de alto grau em doentes com esôfago de Barrett e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É uma situação clínica particular caracterizada por alterações nas células do revestimento do esôfago em pacientes que já apresentam esôfago de Barrett. No sistema internacional de doenças, é identificada pelo código ORPHA:231080 e pelo CID-10 K22.7.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

3 fontes citadas no texto · 9 publicações do grafo RarasNet (PubMed) · 1 base de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. The Impact of Hiatus Hernia Size on Dysplasia Progression in Patients With Barrett's Esophagus.
    JGH open : an open access journal of gastroenterology and hepatology2026PMID 41815942

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (2026). Displasia de alto grau em doentes com esôfago de Barrett. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/displasia-de-alto-grau-em-doentes-com-esofago-de-barrett

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Displasia de alto grau em doentes com esôfago de Barrett

ORPHA:231080
Prevalência
1-5 / 10 000
Herança
Not applicable
CID-10
K22.7 · Esôfago de Barret
CID-11
Início
All ages
Prevalência
36.0 (Europe)
UMLS
C1334003

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Medicamentos aprovados FDA
fonte: FDA OpenFDA
Rara